MedTrace Logo

Meibography and Tear Scan Using the Oculus Keratograph 4

NCT01382108 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2013-11-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to look at both the meibomian glands and the tear film using a new clinical instrument marketed in Canada which was recently acquired by the Centre for Contact Lens Research. These will be compared between two groups of individuals, one group with visible meibomian gland dysfunction (MGD) and one group of individuals with normal meibomian gland appearance. The hypothesis is that there will be a difference between normal individuals and individuals with MGD with respect to the appearance of the meibomian glands and certain tear film attributes.

Conditions

  • Meibomian Gland Dysfunction

Sponsors & Collaborators

  • University of Waterloo

    lead OTHER

Principal Investigators

  • Lyndon Jones, PhD · University of Waterloo

Eligibility

Min Age
17 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01382108 on ClinicalTrials.gov